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Abstract Tyrosine kinases are important cellular signal-
ing proteins that have a variety of biological activities
including cell proliferation and migration. Multiple kinases
are involved in angiogenesis, including receptor tyrosine
kinases such as the vascular endothelial growth factor
receptor. Inhibition of angiogenic tyrosine kinases has been
developed as a systemic treatment strategy for cancer.
Three anti-angiogenic tyrosine kinase inhibitors (TKIs),
sunitinib, sorafenib and pazopanib, with differential bind-
ing capacities to angiogenic kinases were recently
approved for treatment of patients with advanced cancer
(renal cell cancer, gastro-intestinal stromal tumors, and
hepatocellular cancer). Many other anti-angiogenic TKIs
are being studied in phase I-III clinical trials. In addition to
their beneficial anti-tumor activity, clinical resistance and
toxicities have also been observed with these agents. In this
manuscript, we will give an overview of the design and
development of anti-angiogenic TKIs. We describe their
molecular structure and classification, their mechanism of
action, and their inhibitory activity against specific kinase
signaling pathways. In addition, we provide insight into
what extent selective targeting of angiogenic kinases by
TKIs may contribute to the clinically observed anti-tumor
activity, resistance, and toxicity. We feel that it is of crucial
importance to increase our understanding of the clinical
mechanism of action of anti-angiogenic TKIs in order to
further optimize their clinical efficacy.
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Introduction
Cancer development is characterized by uncontrolled cell
growth and proceeds via genetic changes resulting in
numerous biological alterations. Essential hallmarks that
drive tumorigenesis as described by Hanahan and Wein-
berg include: self-sufficiency in growth signals; insensi-
tivity to growth-inhibitory (antigrowth) factors; evasion of
programmed cell death (apoptosis); limitless replicative
potential; sustained angiogenesis; and tissue evasion and
metastasis [1].
Angiogenesis, the growth of new vessels from pre-
existing vasculature, is a critical step in tumor progression
[2]. New blood vessels are required to support the growth
of a tumor beyond the size of about 1–2 mm3, to supply
oxygen and nutrients to proliferating tumor cells and for
metastasis formation [3, 4]. Research in angiogenesis
inhibition as a therapeutic strategy against cancer started
around 1971, when Folkman postulated that tumor growth
is dependent on angiogenesis [5]. In the past two decades,
inhibitors of angiogenesis have been developed for clinical
use [6]. Most notable angiogenesis inhibitors target the
vascular endothelial growth factor (VEGF) signaling
pathway, such as the monoclonal antibody bevacizumab
(Avastin, Genentech/Roche) and two kinase inhibitors
sunitinib (SU11248, Sutent, Pfizer) and sorafenib (BAY43-
9006, Nexavar, Bayer). Bevacizumab was the first angio-
genesis inhibitor that was clinically approved, initially for
treatment of colorectal cancer and recently also for breast
cancer and lung cancer. The small-molecule tyrosine
kinase inhibitors sunitinib and sorafenib target the VEGF
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receptor (VEGFR), primarily VEGFR-2, and have shown
clinical efficacy in diverse cancer types [7, 8]. Both drugs
have shown benefit in patients with renal cell cancer [9,
10]. In addition, sunitinib has been approved for treatment
of gastro-intestinal stromal tumors (GISTs). Sorafenib
inhibits Raf serine kinase as well and has been approved
for treatment of hepatocellular cancer as well [11].
Numerous clinical trials are ongoing with these and other
angiogenesis inhibitors in various cancer types.
Two major problems have been noticed during the
clinical development of angiogenesis inhibitors. In both
preclinical and clinical settings, resistance to angiogenesis
inhibitors occurs. In some patients, treatment with an
angiogenesis inhibitor results in an initial response, fol-
lowed by tumor progression (acquired resistance). In other
patients, intrinsic resistance is being observed [12]. Sec-
ondly, in contrast to initial expectations, significant clinical
toxicities are observed during anti-angiogenic treatment.
These toxicities include severe bleeding, disturbed wound
healing, gastro-intestinal perforation, hypertension, and
fatigue [13].
Insight into the underlying mechanisms of resistance
and toxicities of angiogenesis inhibitors will help to further
improve treatment strategies of angiogenesis inhibition.
This review highlights important tyrosine kinases and their
mediated signaling pathways in angiogenesis. We describe
the molecular structure and classification of tyrosine kinase
inhibitors, their mechanism of action, and their inhibitory
activity against specific kinase signaling pathways. In
addition, we provide insight into what extent selective
targeting of angiogenic kinases by tyrosine kinase inhibi-
tors may contribute to the clinically observed anti-tumor
activity, resistance, and toxicity.
Tyrosine kinases
Kinases, also called phosphotransferases, are enzymes that
transfer a phosphate group from high-energy donor mole-
cules, for example adenosine triphosphate (ATP), to spe-
cific substrates. Protein kinases phosphorylate proteins,
resulting in functional changes of target proteins. Of the
518 protein kinases encoded in the human genome [14], 90
kinases belong to the group of tyrosine kinases. Six other
groups have been identified whose kinases primarily
phosphorylate serine and threonine residues (Fig. 1). The
tyrosine kinase group consists of approximately 30 fami-
lies, for example the VEGFR family and the fibroblast
growth factor receptor (FGFR) family. Apart from classi-
fication in families, tyrosine kinases can also be classified
in receptor tyrosine kinases and non-receptor (cytoplasmic)
tyrosine kinases. Receptor tyrosine kinases are essential for
the transduction of extracellular signals into the cell, while
non-receptor tyrosine kinases accomplish intracellular
communication. A receptor tyrosine kinase monomer
consists of an N-terminal extracellular ligand-binding
domain, a transmembrane domain, and a C-terminal
intracellular domain with tyrosine kinase activity (Fig. 2).
The kinase domain has a bi-lobar structure, with an ATP-
binding cleft located between the N- and C-terminal lobes.
The ATP-binding site can be divided into three subregions:
the adenine region, the sugar region, and the phosphate-
binding region [15]. The C-terminal lobe of kinases con-
tains an activation loop and is marked by a specific amino
acid combination at the start of the loop. This combination
exists of the amino acids aspartic acid, phenylalanine, and
glycine, abbreviated as D, F, and G, respectively, and is
therefore called ‘DFG motif’. The activation loop can
adopt numerous conformations. In the ‘out’ conformation,
the activation loop creates a hydrophobic pocket, nearby
the ATP-binding cleft (Fig. 2). This hydrophobic pocket is
important for a subgroup of tyrosine kinase inhibitors, as
described later.
Ligand binding to the extracellular domain of the
receptor promotes receptor dimerization, resulting in
autophosphorylation of specific tyrosine residues of the
cytoplasmic kinase domain [16]. Besides these phosphor-
ylation sites for regulation of their own kinase activity,
other phosphorylation sites of kinases are being used to
control protein interactions. The activated receptor recruits
interacting proteins that bind to certain phosphorylation
sites [17]. Recruited and phosphorylated signaling proteins
are subsequently able to phosphorylate other proteins.
Activation of (multiple) signaling pathways eventually
leads to biological responses [18]. Biological responses
include cell activation, proliferation, differentiation,
migration, survival, and vascular permeability. We provide
here more insight into signaling pathways and biological
responses of cells involved in angiogenesis, but every cell
uses signaling pathways for their survival, proliferation,
and other activities.
Tumor angiogenesis
In normal physiological circumstances, angiogenesis is
well controlled by pro- and anti-angiogenic factors and is
only promoted during the menstrual cycle, pregnancy, and
during wound healing and repair [19]. Though, in cancer,
this balance of pro- and anti-angiogenic factors is dis-
turbed, resulting in the so-called ‘angiogenic switch’.
Tumor cells secrete a number of pro-angiogenic factors
that stimulate the proliferation and migration of endothelial
cells, resulting in the outgrowth of new capillaries into the
tumor. VEGF signaling through its receptor is the major
inducer of angiogenesis [20]. Therefore, special attention
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Fig. 1 Classification of protein kinases of the human kinome. Protein
kinases can be divided into tyrosine kinases and serine/threonine
kinases. Tyrosine kinases can be subdivided into approximately 30
families, which mediate a variety of biological responses. The kinases
in six other groups mostly phosphorylate serine/threonine residues.
These groups include AGC-containing protein kinase A (PKA)/
protein kinase G (PKG)/protein kinase C (PKC) families; CAMK
calcium/calmodulin-dependent kinase; CK1 casein kinase 1; CMGC-
containing cyclin-dependent kinase (CDK)/mitogen-activated protein
kinase (MAPK)/glycogen synthase kinase (GSK)/CDK-like kinase
(CLK) families; STE homologues of yeast sterile 7, sterile 11, sterile
20 kinases; TKL tyrosine kinase-like kinase. Each of these groups can
also be classified into families, of which at least one example per
group is shown. ABL Abelson kinase; Akt Akt/protein kinase B
(PKB); EGFR epidermal growth factor receptor; FGFR fibroblast
growth factor receptor; MLK mixed-lineage kinase; PDGFR platelet-
derived growth factor receptor; TIE tyrosine kinase with immuno-
globulin-like and EGF-like domain; VEGFR vascular endothelial
growth factor receptor
Fig. 2 Structure of a receptor tyrosine kinase. The extracellular
domain of a receptor tyrosine kinase can bind specific ligands such as
growth factors, while the intracellular domain achieves (auto)phos-
phorylation of the kinase. The extra- and intracellular domain are
parted by the transmembrane region that is anchored in the cell
membrane. The ATP-binding cleft is located between the two lobes of
the intracellular domain. A schematic representation of the ATP-
binding cleft, with its different regions, is shown on the right side of
the figure. The binding regions of type I and type II tyrosine kinase
inhibitors are indicated
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has been paid on inhibition of this receptor tyrosine kinase
to block formation of new blood vessels in cancer [6]. Anti-
angiogenic tyrosine kinase inhibitors that have shown
clinical activity in phase I/II clinical trials are listed in
Table 1.
Tyrosine kinases and growth factors involved in
angiogenesis
The tyrosine kinase VEGFR is a crucial mediator in
angiogenesis. The VEGFR family comprises three related
receptor tyrosine kinases, known as VEGFR-1, -2, and -3,
which mediate the angiogenic effect of VEGF ligands [21].
The VEGF family encoded in the mammalian genome
includes five members: VEGF-A, VEGF-B, VEGF-C,
VEGF-D, and placental growth factor (PlGF). VEGFs are
important stimulators of proliferation and migration of
endothelial cells. VEGF-A (commonly referred to as
VEGF) is the major mediator of tumor angiogenesis and
signals through VEGFR-2, the major VEGF signaling
receptor [20]. A second important growth factor involved
in angiogenesis is the platelet-derived growth factor
(PDGF). The PDGF family consists of at least four mem-
bers: PDGF-A, PDGF-B, PDGF-C, and PDGF-D, which
bind to two different receptors, known as PDGFR-a and -b
[22]. PDGFs facilitate recruitment of pericytes and smooth
muscle cells and are important for maturation and stability
of the vasculature [23]. Also, basic fibroblast growth factor
(bFGF), known as FGF2 as well, has important angiogenic
properties. The 18 members of FGF family can be divided
into six subfamilies and bind to seven main FGF receptors.
FGF2 induces angiogenesis by stimulating migration and
proliferation of endothelial cells. Furthermore, it supports
proliferation of smooth muscle cells and fibroblasts [24].
Tyrosine kinase signaling in angiogenesis
Stimulation of VEGFRs and other tyrosine kinase receptors
causes massive activation of signaling pathways in endo-
thelial cells. Signaling molecules downstream of receptor
tyrosine kinases not only include tyrosine kinases, but
involves other signaling proteins as well including serine/
threonine kinases and G-proteins. Important signaling
molecules recruited to tyrosine kinase receptors comprise
proteins with a Src homology 2 (SH2) domain. Association
of a phosphorylated tyrosine kinase receptor with a SH2
domain-containing protein results in the phosphorylation
and activation of this effector protein. In addition, the
Table 1 Anti-angiogenic tyrosine kinase inhibitors in clinical development
Agent Target Clinical activity and/or study Phase of development Refs
Sunitinib
(SU11248;
Sutent)
VEGFR-1, -2, -3,
PDGFR, KIT,
FLT3, CSF-1R,
RET
Kidney, breast, prostate, lung, liver,
ovarian, colorectal, thyroid, head and
neck, gastric, bladder, cervical and
pancreatic cancer, GIST, melanoma,
glioblastoma, myeloma, lymphoma
Approved for kidney cancer
and GIST, phase II or III for
other cancers
[7, 9]
Sorafenib
(BAY439006;
Nexavar)
VEGFR-2, -3,
PDGFR, Raf, KIT
Kidney, liver, breast, prostate, lung,
ovarian, colorectal, thyroid, head and
neck, gastric and pancreatic cancer,
GIST, melanoma, glioblastoma,
lymphoma, leukemia
Approved for kidney and liver
cancer, phase II or III for
other cancers
[8, 11]
Pazopanib
(GW786034;
Votrient)
VEGFR-1, -2, -3,
PDGFR, KIT
Kidney, breast, lung, cervical, liver,
thyroid, prostate and colorectal cancer,
melanoma, glioblastoma
Approved for kidney cancer,
phase II or III for other
cancers
[99, 100]
Vandetanib
(ZD6474;
Zactima)
VEGFR-2, EGFR,
KIT, RET
Lung, kidney, thyroid, head and neck,
prostate, ovarian, breast and colorectal
cancer, glioma, neuroblastoma
Phase II or III [53, 101, 102]
Axitinib
(AG013736)
VEGFR-1, -2, -3,
PDGFR-b, KIT
Kidney, lung, thyroid, pancreatic,
colorectal and breast cancer, melanoma
Phase II or III [103, 104]
Cediranib
(AZD2171;
Recentin)
VEGFR-1, -2, -3,
PDGFR-b, KIT
Kidney, breast, lung, liver, ovarian, head
and neck, prostate and colorectal
cancer, GIST, glioblastoma, melanoma
Phase II [105, 106]
Vatalanib
(PTK787;
ZK222584)
VEGFR-1, -2, -3,
PDGFR-b, KIT
Prostate, colorectal, kidney and
pancreatic cancer, melanoma,
lymphoma, leukemia
Phase II or III [107, 108]
Motesanib
(AMG706)
VEGFR-1, -2, -3,
PDGFR, KIT, RET
Lung, thyroid, gallbladder, breast and
colorectal cancer, GIST
Phase II or III [109, 110]
CSF-1R colony stimulating factor-1 receptor, EGFR epidermal growth factor receptor, FLT3 fms-related tyrosine kinase 3, GIST gastro-intestinal
stromal tumor, PDGFR platelet-derived growth factor receptor, VEGFR vascular endothelial growth factor receptor
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binding of this SH2 domain-containing protein to the
receptor serves as a docking site for other signaling mol-
ecules. Phospholipase C-c (PLCc) is an SH2 domain-con-
taining protein that is frequently involved in signaling by
VEGFRs. PLCc phosphorylates protein kinase C (PKC)
[25], which subsequently phosphorylates a range of kina-
ses. Phosphorylation of MEK (mitogen-activated protein
kinase (MAPK) and extracellular-signal-regulated kinase
(ERK) kinase) by PKC stimulates the p42/44 MAPK
pathway [26]. Phosphorylated MAPK, a serine/threonine
kinase, activates various transcription factors and is known
to regulate cell proliferation (Fig. 3a).
Another signaling molecule involved in the MAPK
cascade is the growth factor receptor-bound protein 2
(Grb2) [27]. Grb2 contains SH2 and SH3 domains and is
able to activate the G-protein Ras via association with the
ATP/ADP exchange factor mammalian Son-of-sevenless
(Sos) [28]. The Ras protein can bind to and phosphorylate
Raf, which in turn can activate the MEK/MAPK pathway.
The Ras/Raf pathway is a classical pathway in activation of
MAPK and is involved in signaling of many tyrosine
kinase receptors, for example, the epidermal growth factor
receptor (EGFR). However, activation of the Ras/Raf
pathway plays a minor role in VEGFR signaling [29].
An adapter molecule that is important in VEGFR-
mediated signaling is the SH2 and b-cells (Shb) protein.
Interaction of Shb with a specific phosphorylation site of
VEGFR-2 activates phosphatidylinositol 30-kinase (PI3K).
PI3K and its downstream activated serine/threonine kinase
Akt/protein kinase B (PKB) are involved in several
important processes of angiogenesis, including endothelial
cell migration, proliferation, and survival, as shown in
Fig. 3b. Activation of Akt/PKB requires generation of
phosphatidylinositol 3,4,5-triphosphate (PIP3) by PI3K-
mediated phosphorylation of phosphatidylinositol 4,5-
biphosphate (PIP2) [30]. Akt/PKB stimulates proliferation
and survival by the activation or inhibition of a variety of
substrates [31]. Akt/PKB phosphorylates and inhibits the
pro-apoptotic protein BAD (Bcl-2 associated death pro-
moter) as well as GSK3 (glycogen synthase kinase 3). Akt/
PKB is also able to activate the mammalian target of
rapamycin (mTOR) and its downstream p70S6K which are
regulators of cell proliferation and survival [32]. In addi-
tion, Akt/PKB enhances cellular proliferation through
activation of nuclear factor-jB (NF-jB) [33]. Furthermore,
Akt/PKB is able to stimulate vasodilation, vascular
remodeling, and angiogenesis, through phosphorylation of
endothelial nitric oxide (NO) syntheses (eNOS) [34]. Last,
but not least, the PI3K pathway seems to be involved in
endothelial cell migration [35]. Other signaling molecules
that are involved in (endothelial) cell migration are shown
in Fig. 3a and include the T-cell specific adaptor (TSAd)
protein, p38 MAPK, and the focal adhesion kinase (FAK)
[36]. TSAd binds to other phosphorylation site of the
VEGFR-2 than PLCc and Shb. Activated TSAd forms
complexes with Src and regulates cell migration and vas-
cular permeability [37]. Interaction of p38 MAPK with a
phosphorylation site of the VEGFR-2 mediates actin
reorganization and cell migration [38]. Activated FAK is
capable of controlling diverse aspects of cell migration,
Fig. 3 Signal transduction pathways and biological processes med-
iated by receptor tyrosine kinases focused on angiogenesis. a A
selection of pathways activated by receptor tyrosine kinase involved
in angiogenesis is shown. Pathway activation, for example by VEGFR
or PDGFR, can result in a variety of angiogenic processes, such as
cell proliferation, migration, survival, and vascular permeability. b
The phosphatidylinositol 30-kinase (PI3K) pathway is an important
downstream pathway of diverse receptor tyrosine kinases and is
involved in various cellular processes in angiogenesis. Akt/protein
kinase B (PKB) is activated downstream of PI3K. BAD Bcl-2-
associated death promoter; eNOS endothelial nitric oxide synthase;
FAK focal adhesion kinase; Grb2 growth factor receptor-bound
protein 2; GSK3 glycogen synthase kinase 3; MAPK mitogen-
activated protein kinase; MEK MAPK and extracellular-signal-
regulated kinase (ERK) kinase; mTOR mammalian target of rapamy-
cin; NF-jB nuclear factor-jB; PIP3 phosphatidylinositol 3,4,5-
triphosphate; PKC protein kinase C; PLCc phospholipase C-c;
p70S6K p70S6 kinase; Shb SH2 and b-cells; TSAd T-cell specific
adaptor
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including regulation of the cytoskeleton and influences
structures of cell adhesion sites [39]. FAK has also been
shown to maintain survival signals in endothelial cells [40].
Tyrosine kinase inhibitors
Metabolism of tyrosine kinase inhibitors
Tyrosine kinase inhibitors are small molecules and are in
contrast to monoclonal antibodies able to pass through the
cell membrane [41]. Monoclonal antibodies can only act on
molecules expressed on the cell surface or on secreted
molecules. Small-molecule inhibitors are largely hydro-
phobic and can easily enter the cell where they can interact
with the intracellular domain of receptors and intracellular
signaling molecules. As a result, small-molecules kinase
inhibitors are able to block the activation of various
downstream signaling pathways intracellularly. Tyrosine
kinase inhibitors can be taken orally, if necessary in a salt
form of the inhibitor. For example, sunitinib is taken as
sunitinib malate (the malate salt of sunitinib) [42], while
sorafinib is taken as tosylate sorafenib (the tosylate salt of
sorafenib) [43]. Tyrosine kinase inhibitors are being
administered to patients at a fixed dose once or twice daily,
because the variability in pharmacokinetics of these agents
is not significantly affected by weight [44]. Some of the
tyrosine kinase inhibitors are metabolized by the liver pri-
marily by cytochrome-P enzymes. For example, sunitinib is
metabolized primarily by the cytochrome P450 enzyme
CYP3A4 [42]. The parent compound and active metabolite
have similar biochemical activity and potency. The primary
metabolite is further metabolized by CYP3A4 to its sec-
ondary inactive metabolite [45]. Also, other enzymes are
involved in the metabolism of sunitinib. Van Erp et al. [46]
investigated polymorphisms genotyped in the pharmacoki-
netic and pharmacodynamic pathways of sunitinib and
studied their association with sunitinib-induced toxicities.
Half-life times of sunitinib and its primary metabolite are
approximately 40–60 h and 80–110 h, respectively [42].
Elimination of sunitinib is primarily via feces [45].
Sorafenib undergoes oxidative metabolism, mediated by
CYP3A4, as well as glucuronidation, mediated by UGT1A9
[43]. Several metabolites of sorafenib have been identified,
of which the main circulating metabolite, the pyridine N-
oxide, shown potency similar to that of sorafenib in vitro.
Sorafenib elimination half-time is between 25 and 48 h, and
it is secreted in feces as well as in urine [43].
Modes of tyrosine kinase inhibitor binding
Most small-molecule kinase inhibitors discovered to date
compete with ATP. The chemical structure of ATP is
shown in Fig. 4a. ATP consists of adenosine, composed of
an adenine ring and a ribose sugar, and three phosphate
groups. Binding of ATP to a kinase is characterized by the
formation of hydrogen bonds from the adenine ring to the
ATP-binding cleft of the kinase. Kinase inhibitors can
target (nearby) the ATP-binding site of a kinase. The ATP-
binding site is common to all protein kinases, and selec-
tivity of kinase inhibitors is engineered by the chemical
structure which is not similar to the ATP structure. The
chemical structures of the anti-angiogenic tyrosine kinase
inhibitor listed in Table 1 are shown in Fig. 4b. Elements
of some compounds can be compared to elements of ATP.
For example, the adenine ring of ATP, which forms
Fig. 4 Chemical structures of ATP and anti-angiogenic tyrosine
kinase inhibitors. a Chemical structure of ATP. ATP consists of an
adenine ring, a ribose sugar, and three phosphate groups. The adenine
ring, which forms hydrogen bonds with the ATP-binding site of its
target kinase, is encircled in this figure. b Chemical structures of the
anti-angiogenic tyrosine kinase inhibitors sunitinib, sorafenib, paz-
opanib, vandetanib, axitinib, cediranib, vatalanib, and motesanib. The
targets of these inhibitors, their clinical activity, and their phase of
development are listed in Table 1
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hydrogen bonds to the kinase, is in more or lesser similarity
seen in pazopanib, vatalanib, and axitinib.
Tyrosine kinase inhibitors can be subdivided in cate-
gories. Here, we classify tyrosine kinase inhibitors in three
different types and focus on anti-angiogenic tyrosine
kinase inhibitors. Type I kinase inhibitors recognize the
active conformation of a kinase. They bind to the ATP-
binding site by presenting one to three hydrogen bonds
which mimic the hydrogen bonds normally formed by ATP
[47]. An example of a type I tyrosine kinase inhibitor
targeting the VEGF pathway is sunitinib. Sunitinib demon-
strated competitive inhibition to ATP against VEGFR-2
(Flk-1) and PDGFR-b [48]. Sunitinib is furthermore a
well-known inhibitor of VEGFR-1 and -3, PDGFR-a, KIT,
fms-related tyrosine kinase 3 (FLT3), colony stimulating
factor-1 receptor (CSF-1R), and RET [7]. It is expected to
compete with ATP by presenting several hydrogen bonds
to the ATP-binding site [47, 49].
In contrast to type I kinase inhibitors, type II kinase
inhibitors recognize the inactive conformation of a kinase.
Type II inhibitors indirectly compete with ATP by occu-
pying the hydrophobic pocket which is directly adjacent to
the ATP-binding site. This hydrophobic pocket is created by
the DFG-out conformation of the activation loop. This
unique DFG-out conformation is also known as the allo-
steric site, and type II inhibitors can modulate kinase
activity in an allosteric way. Some type II inhibitors are able
to form a hydrogen bond directly to the ATP-binding site,
while this is not necessary for functionality [15]. Sorafenib
is a type II kinase inhibitor [50] and blocks the phosphor-
ylation of VEGFR, PDGFR, Raf, and KIT by using a
hydrophobic pocket to (indirectly) compete with ATP. It
binds to its target kinases in an inactive conformation [49].
A third class of kinase inhibitors is known as ‘covalent’
inhibitors. These inhibitors have been developed to cova-
lently bind to cysteines at specific sites of the kinase. Sulfur
(S), present in the cysteine residue, is an electron-rich atom,
which reacts with an electrophilic group of the inhibitor. As
a result, the inhibitor and the cysteine residue irreversibly
bind by sharing electrons. This allows the inhibitor to block
binding of ATP to the kinase and prevents activation of the
kinase [51]. Examples of covalent tyrosine kinase inhibitors
are quinazoline-based inhibitors [52] such as vandetanib
(ZD6474, Zactima, AstraZeneca), which in addition to
targeting VEGFR, inhibits EGFR [53]. This inhibitor is an
anilquinazoline derivate, and inhibits activation of kinases
by covalently bind to a cysteine group of the kinase.
Binding regions of type I and type II inhibitors in ATP-
binding cleft of the kinase are indicated in Fig. 2. Because
covalent inhibitors bind a cysteine residue which can be
variably located in the kinase domain, the binding site of
this inhibitor type is not illustrated.
Selectivity of tyrosine kinases inhibitors
Many anti-angiogenic tyrosine kinase inhibitors are so-
called multi-targeted kinase inhibitors. These agents target
a number of different kinases, which are involved in sev-
eral signaling pathways. It is reasonable to expect that
inhibitors of multiple kinases possess a broader efficacy
than a single-targeted inhibitor. For example, the VEGF
pathway and PDGF pathway both play important roles in
angiogenesis. For inhibition of angiogenesis, it is expected
that a multi-targeted kinase inhibitor that blocks VEGFR
signaling as well as PDGFR signaling will be more
effective than an inhibitor that targets only one of these
pathways.
On the other hand, inhibitors should be highly selective
to minimize treatment-induced toxicities [54]. Toxicities
observed in treatment with tyrosine kinase inhibitors are
diverse, varying from more general complications like
diarrhea and nausea to specific toxicities like hand foot
syndrome. Most common toxicities of the anti-angiogenic
tyrosine kinase inhibitors sunitinib and sorafenib include
hypertension, bleeding, fatigue, diarrhea, nausea and/or
vomiting, hand foot syndrome, and myelosuppression [54,
55]. Other toxicities with a low frequency include hypo-
thyroidism, impaired kidney function, and reversible pos-
terior leukoencephalopathy syndrome. In addition, during
sunitinib treatment, hemoglobin levels and erythrocyte
numbers transiently increase [56]. The anti-angiogenic
monoclonal antibody bevacizumab blocks the VEGF
ligand and inhibits angiogenesis [57]. Most commonly
reported toxicities induced by bevacizumab are hyperten-
sion, proteinuria, bleeding, fatigue, and gastro-intestinal
symptoms [54, 58, 59]. Since these toxicities highly over-
lap with toxicities induced by anti-angiogenic tyrosine
kinase inhibitors, these toxicities are expected to be related
to the targeted (VEGF) pathway. Molecular mechanisms
involved in toxicities of targeting the VEGF pathway are
discussed by Verheul and Pinedo [13], and by Kamba and
McDonald [59].
Tyrosine kinases have a high degree of similarity in the
kinase domain. The ATP-binding site is most similar,
because of its need to bind ATP for its activity. These
binding sites are highly conserved across the kinome. Type
I inhibitors invariably occupy the adenine region in the
ATP-binding site, and for that reason, it is difficult to
develop highly selective type I inhibitors. Inhibitors against
less conserved regions of a kinase can be more selective
[33]. Selective kinase targeting can be easier achieved
within type II inhibitors, because more variability is seen
among kinases in their inactive conformation [60]. Cova-
lent inhibitors should be very selective due to their irre-
versible mechanism of binding to a cysteine residue of the
Angiogenesis (2010) 13:1–14 7
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target kinase. Unexpected targets of covalent inhibitors
could result in serious toxicities.
Selectivity of kinase inhibitors is hard to predict when
only based on structure and sequence. Specificity profiles of
kinase inhibitors can be analyzed by assessment of binding
affinities. Fabian and colleagues reported inhibitor–kinase
interaction maps for a number of kinase inhibitors, includ-
ing sunitinib, vatalanib, and vandetanib [61]. The dissoci-
ation constant (Kd) was used to describe the binding affinity;
the smaller the dissociation constant, the higher the affinity
of the inhibitor to a kinase. Selectivity varied largely among
agents that are presumed to target the same kinase. Vat-
alanib specifically binds VEGFR-2, while sunitinib binds
many additional kinases. The binding affinities of different
inhibitors vary substantially with dissociation constants of
less than 1nM to some target kinases, to 1–10 lM to ‘non-
target’ kinases. Although some inhibitors show (low)
affinity to a large proportion of kinases, these assays mea-
sure binding affinity, and no conclusions can be drawn on
activity of the inhibitor. It is important to realize that a low
binding affinity of a tyrosine kinase inhibitor to a certain
kinase may have a crucial impact on cell signaling, while
the same inhibitor with a high binding affinity to another
kinase may have no significant intracellular downstream
effect. Not only inhibition of a specific tyrosine kinase, but
also the expression level of a kinase and the number of
potential parallel pathways (other kinases) determine the
downstream biological efficacy of a tyrosine kinase inhib-
itor. It is important to get more insight into the relative
importance of targeted kinases and the alternative activity
routes of kinases in cancer. Several approaches to determine
kinase activities in tumor samples are being explored in
preclinical studies and in the clinical setting [62–64]. We
expect that high throughput analyses of kinome activity
profiles in tumors from patients can be used to select spe-
cific kinase inhibitors for treatment of patients, so-called
personalized medicine.
Drug resistance
Drug resistance in patients treated with anti-angiogenic
therapies is an important clinical problem [65]. Tumors
may acquire resistance during anti-angiogenic treatment or
show intrinsic resistance. The majority of patients tran-
siently benefits from anti-angiogenic therapy, before a
tumor recovers and starts to grow again and forms metas-
tases. A small fraction of patients fails to show even initial
clinical benefit [12].
One possible mechanism involved in treatment resis-
tance might be the excess of signaling pathways which are
involved in angiogenesis. Although VEGF-mediated sig-
naling is the predominant stimulator of angiogenesis in
cancer, parallel angiogenic pathways also drive tumor
growth. Activation of these pathways may overcome
inhibition by anti-angiogenic tyrosine kinase inhibitors. For
example, Delta-like 4 (Dll4)-mediated Notch signaling
represents an important pathway in angiogenesis, and
inhibition of this pathway results in excessive, non-pro-
ductive angiogenesis and in reduced tumor growth [66]. It
has been suggested that Dll4/Notch signaling might be
involved in resistance to anti-VEGF therapy [67], and that
this pathway might be responsible for the escape from anti-
angiogenic therapy. Also, the Tie receptors, together with
their two major ligands, angiopoietin-1 (Ang-1) and an-
giopoietin-2 (Ang-2), are alternative pathways to induce
biological responses involved in angiogenesis, such as
vessel maturation [68]. The PI3K/Akt pathway is an
example of a downstream signaling pathway of VEGFR,
which can also be activated by angiopoietin-Tie signaling
[29]. Inhibition of VEGFR-mediated pathways might not
be sufficient to completely inhibit signaling pathways
involved in angiogenesis, and as a result, tumors are able to
grow and progress despite inhibition of the VEGF pathway.
VEGF was discovered as an endothelial cell mitogen
and functions as an angiogenesis stimulator [69]. This
suggested that VEGF acts by binding to receptors present
on endothelial cells. De Vries et al. [70] determined fms-
like tyrosine kinase (Flt-1) as a receptor for VEGF, now-
adays also known as VEGFR-1. Fetal liver kinase-1 (Flk-
1), the mouse homologue of kinase insert domain-con-
taining receptor (KDR), was shown to be a second func-
tional VEGF receptor and was demonstrated to play a role
in angiogenesis [71–73]. Quinn et al. [72] demonstrated
that Flk-1 in the mouse embryo exclusively is expresses in
the vascular endothelium and the umbilical cord stroma.
Nowadays, stimulation of VEGFR on (tumor) endothelium
by VEGF is well known. However, VEGFRs may also be
present on tumor cells, as has been shown by several
studies listed by Hicklin and Ellis [21]. For that reason, it
could be hypothesized that VEGF is also able to stimulate
tumor cells expressing VEGFRs. Inhibitors of VEGFR may
not only restrain tumor growth by the inhibition of tumor
angiogenesis, but exert additional inhibitory effects on
tumor cells [74]. We have recently found that the anti-
angiogenic tyrosine kinase inhibitor sunitinib inhibits
tumor cell proliferation and clonogenic capacity directly
[75]. Therefore, acquired resistance may also be a conse-
quence of alternative signaling of tumor cells including the
production of alternative angiogenic growth factors.
Resistance to kinase inhibitors as result of a mutation in
the target kinase in tumor cells is a well-known mechanism
and is described for inhibitors such as gefitinib and erl-
otinib. These two inhibitors target the epidermal growth
factor receptor (EGFR) and are used for treatment of
patients with non-small cell lung cancer and several other
8 Angiogenesis (2010) 13:1–14
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types of cancer. Somatic activating mutations in the EGFR
have been associated with sensitivity to these agents [76,
77]. Despite clinical responses to these inhibitors, most
patients acquire resistance during treatment. One mecha-
nism of acquired resistance is a specific secondary muta-
tion in the EGFR. In the presence of this secondary
mutation, the kinase inhibitors are unable to inhibit phos-
phorylation of the target kinase [78].
Initially, resistance to anti-angiogenic tyrosine kinase
inhibitors was not expected, because these agents were
supposed to target endothelial and other stroma cells which
are genetically stable and therefore unlikely to develop
mutations. However, now, we know that anti-angiogenic
tyrosine kinase inhibitors may also inhibit tumor cells
directly, mutations in target receptors are more likely to
occur and should be explored as possible mechanisms of
resistance. Recently, several studies reported mutations in
target kinases that correlate with resistance to sunitinib in
imatinib-resistant gastro-intestinal stromal tumors (GISTs)
[79–82]. Heinrich et al. [79] determined mutational status of
KIT and PDGFR-a in tumors of patients with metastatic,
imatinib-resistant or intolerant GISTs. They reported that
primary and secondary mutations in these kinases influence
sunitinib activity. Clinical benefit and objective response
rates with sunitinib were higher in patients with primary
KIT exon 9 mutations than with exon 11 mutations. In vitro,
sunitinib activity against KIT double mutants was depen-
dent on location of the second mutation. The PDGFR-a
D842V mutant conferred resistance to imatinib as well as to
sunitinib in in vitro experiments. Nishida et al. analyzed
KIT mutations in patients with imatinib-resistant GISTs,
who had been treated with sunitinib [80]. They reported that
the pre-imatinib sample had KIT mutations in exon 9 or
exon 11 (n = 8), and most imatinib-resistant tumors carried
a secondary mutation. Most patients with a secondary
mutation in exon 13 or 14 (the ATP-binding domain)
obtained clinical benefits from sunitinib, while most tumors
with a secondary mutation in exon 17 (the activation loop)
showed resistance to the drug. All secondary (and tertiary)
mutations were located on the same allele as the primary
mutation, so-called cis-mutations. Also, Guo et al. [81]
investigated mutations in KIT conferring sunitinib resis-
tance in GIST. They found that secondary mutations in the
KIT activation domain are associated with sunitinib resis-
tance after initial response to the drug. Gajiwala et al. [82]
investigated the molecular basis of resistance to sunitinib in
GIST. They reported that the KIT mutants D816H and
D816V undergo a change in conformational equilibrium.
The conversion from the inactivated kinase conformation to
the active conformation results in a drug-insensitive active
form and causes loss of inhibition.
Toxicities of tyrosine kinase inhibitors
Toxicities of anti-angiogenic tyrosine kinase inhibitors
might be due to inhibitors with multiple so-called ‘off-
targets’. However, selective inhibitors may also induce
toxicities, because their target kinases are not differentially
expressed by endothelial cells. Angiogenesis inhibitors are
intended to target activated tumor endothelium. Initially,
these agents were not expected to target normal vascula-
ture, because most blood vessels remain quiescent during
adulthood [19]. However, under normal physiological cir-
cumstances, growth factor signaling in endothelial cells
seems important for their survival and maintenance of
vascular integrity. Inhibitors of angiogenesis are capable of
affecting signaling pathways in endothelial cells and might
elicit toxicities as a result of decreased endothelial cell
renewal capacity [83].
Apart from kinase inhibitors with ‘off-targets’ activi-
ties, downstream signaling pathways of target kinases
may also be involved in the development of toxicities. As
shown earlier, one kinase is able to activate several
downstream signaling pathways. By inhibition of a kinase
with a tyrosine kinase inhibitor, a whole spectrum of
signaling pathways can be deactivated. This might result
in a reduction in specific biological outcomes which are
not intended to adjust. It has been shown that specific
kinases are involved in the normal physiology of certain
organs such as kidneys and the thyroid gland. It has been
suggested that specific toxicities, like nephrotic syndrome
and fatigue, might be related to interference of these
inhibitors with the normal function of these organs [84,
85]. Furthermore, bleeding complications (including sub-
ungual bleedings) and wound healing problems may be
caused by a disturbance of the close interaction of
platelets with the vasculature [13]. In preliminary exper-
iments, we have found that platelet function is disturbed
by anti-angiogenic kinase inhibitors (Walraven et al.,
preliminary results). Another factor involved in toxicity
might be an altered pharmacodynamic effect of sunitinib
treatment due to certain gene variances as recently
reported by Van Erp et al. [46]. These investigators
analyzed in a group of 219 patients treated with single
agent sunitinib a total of 31 single nucleotide polymor-
phisms (SNPs) in 12 candidate genes, together with sev-
eral non-genetic variants and found a correlation between
sunitinib-induced leucopenia and SNP-variants. We
expect that genetic analyses will be included in routine
screening before start of treatment with kinase inhibitors
to predict for treatment-related toxicity. Based on this
type of analyses, dose adjustments or alternative kinase
inhibitor treatment options can be considered.
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Optimal treatment strategy: multi-targeted inhibitors
and combining inhibitors
Resistance is less likely to arise if multiple regulatory
molecules are being targeted at the same time [86]. Multi-
targeted kinase inhibitors are able to target various sig-
naling molecules. This may inhibit multiple parallel
downstream signaling pathways or enhance inhibition of
one specific shared signaling pathway downstream of
several signaling molecules. Moreover, a drug with mul-
tiple so-called ‘off-target’ effects binds less precisely to
its target kinases and is for that reason less sensitive for
dislodging due to a mutation of the target kinase [87].
A decreased incidence of resistance or a delay in its
development may also be achieved by combining agents
[88]. Anti-angiogenic tyrosine kinase inhibitors can vari-
ously be combined. First, anti-angiogenic tyrosine kinase
inhibitors can be combined with other anti-angiogenic
agents. Tyrosine kinase inhibitors could be combined to
simultaneously inhibit multiple-linked signaling pathways.
Besides ‘horizontal’ inhibition of signaling pathways,
inhibition in a ‘vertical’ strategy could enhance therapy
efficacy; drugs are combined to inhibit a cascade of sig-
naling molecules [74, 89, 90]. By inhibition in a ‘vertical’
strategy, feedback loops in the network of signaling
pathways may be circumvented. Feedback loops are
important regulators of signaling pathway [90] and might
be involved in unexpected and undesirable outcomes of
targeting therapies. For example, feedback loops might be
involved in the (absence of) response to sorafenib therapy
in melanomas. Although sorafenib is developed as a Raf
inhibitor, some discussion is going on whether sorafenib
does certainly inhibit Raf. Activating mutations of B-Raf
are present in approximately 70% of the human melano-
mas [91, 92]. These activating B-Raf mutations may
result in an increased activity of the downstream protein
MAPK. In human melanoma cell lines, it is shown that
apoptosis is increased when B-Raf expression is down-
regulated using RNA interference, suggesting that B-Raf
is a therapeutic target in melanomas [93]. However, in a
phase II clinical trial, it is found that sorafenib has little
or no anti-tumor effect in patients with advanced mela-
noma [94]. In addition, the addition of sorafenib to car-
boplatin and paclitaxel (CP) did not improve therapy
outcomes compared to CP and placebo [95]. It is possible
that sorafenib is not strong enough to inhibit (all) the
activated mutant B-Raf, although it shows an IC50 of
38nM to the oncogenic B-Raf V600E [8]. Another pos-
sibility is that several feedback loops downstream of
B-Raf compensate for the B-Raf inhibition. Downstream
proteins of B-Raf, for example MAPK, might still be
activated by feedback loops, while B-Raf itself is inhib-
ited. Targeting a cascade of signaling molecules might
avoid downstream responses to be still activated through
triggering of feedback loops.
Targeting a cascade of signaling molecules could also be
helpful when it is unknown which proteins are important in
the development of resistance to targeted therapy. Kinases
with a high expression level are not necessary ‘key’ kinases
of signaling pathways. Kinases with a low expression level
can have a high activity and may be crucial for a signaling
pathway. Defining key kinases in a signaling pathway might
improve the use of targeted therapies, but it is hard to define
which protein is most important. By targeting several pro-
teins in the same signaling pathway, this problem may partly
be avoided. As shown earlier, downstream signaling path-
ways of receptor tyrosine kinases include not only tyrosine
kinase but also serine/threonine kinases. For that reason,
combining tyrosine kinase inhibitors with serine/threonine
inhibitors might be a worthwhile strategy, as well as com-
bining anti-angiogenic tyrosine kinase inhibitors with the
anti-VEGF monoclonal antibody bevacizumab.
A second strategy to combine anti-angiogenic agents
comprises the combination with other anti-cancer thera-
peutics, for example conventional cytotoxic chemotherapy.
It is hypothesized that anti-angiogenic agents can induce
vessel normalization of the structurally and functionally
abnormal tumor vasculature [96]. This may result in
improved delivery of cytotoxic drugs and oxygen to the
tumor and could enhance the efficacy of chemotherapy or
radiation therapy [97]. In addition, it is suggested that
chemotherapy and radiation therapy may also directly
damage endothelial cells, and thus may enhance anti-
angiogenic effects [21, 97]. Furthermore, combining anti-
angiogenic agents with chemotherapy potentially delays
the development of resistance to anti-angiogenic drugs as
well as to chemotherapy [96, 98]. The monoclonal anti-
body bevacizumab is in combination with chemotherapy
approved for several (metastatic) cancers. Currently, many
clinical trials are ongoing to study the combination of anti-
angiogenic tyrosine kinase inhibitors with chemotherapy or
radiation therapy.
Of course, one should realize that combination of
different inhibitors or generating broader targeting inhib-
itors will induce more toxicity as well. Therefore, anal-
yses of the tumor kinome profile (genetically or with real
activity analyses) from each single patient by high
throughput analyses may provide specific kinome profiles
that should be targeted at once. We expect that combi-
nation of currently available or newly designed specific
inhibitors may be prescribed based on these kinome
profiles as a standard way of personalized treatment.
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Conclusions and perspectives
Targeting angiogenesis to inhibit tumor growth has been
developed as a new anti-cancer treatment strategy in the
past few decades. Anti-angiogenic therapies show clinical
efficacy in diverse cancer types. Since many different
regulatory factors and signaling pathways are involved in
angiogenesis, therapies targeting angiogenesis are quite
susceptible for causing toxicity and drug resistance. With
respect to the excess of signaling pathways downstream of
certain kinases, selective tyrosine kinase inhibitors have
some advantages in order to minimize the induction of
toxicities. On the other hand, multi-targeted kinase inhib-
itors, or a combination of inhibitors, may target additional
angiogenic pathways and may carry out a broader efficacy
and may avoid resistance. It is important to get more
insight into the signaling pathways that are modified by the
use of (anti-angiogenic) kinase inhibitors. A better under-
standing of patient-specific kinomes including alterations
in signaling pathways may circumvent treatment-induced
resistance and toxicities of anti-angiogenic agents leading
to improved clinical benefit.
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